Randomized Phase III Trial of Radical Radiotherapy with Concurrent Carbogen and Nicotinamide in Locally-advanced Bladder Cancer

Abstract

A pilot study in advanced bladder cancer of accelerated radiotherapy with concurrent carbogen and nicotinamide (RT+CN) suggested a therapeutic advantage relative to radiotherapy alone (RT). Subsequently, between 2000 and 2006, 333 patients have been recruited into a Phase-III randomized trial comparing RT+CN (n = 168) with RT (n = 165).